- Home
- CDTG vs TENX Comparison
CDTG vs TENX Comparison
Compare CDTG & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- TENX
- Stock Information
- Founded
- CDTG 2012
- TENX 1967
- Country
- CDTG China
- TENX United States
- Employees
- CDTG N/A
- TENX N/A
- Industry
- CDTG
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- TENX Health Care
- Exchange
- CDTG NYSE
- TENX Nasdaq
- Market Cap
- CDTG 24.5M
- TENX 21.6M
- IPO Year
- CDTG 2024
- TENX N/A
- Fundamental
- Price
- CDTG $0.90
- TENX $6.05
- Analyst Decision
- CDTG
- TENX Strong Buy
- Analyst Count
- CDTG 0
- TENX 3
- Target Price
- CDTG N/A
- TENX $16.00
- AVG Volume (30 Days)
- CDTG 137.7K
- TENX 24.4K
- Earning Date
- CDTG 05-15-2025
- TENX 08-12-2025
- Dividend Yield
- CDTG N/A
- TENX N/A
- EPS Growth
- CDTG N/A
- TENX N/A
- EPS
- CDTG 0.14
- TENX N/A
- Revenue
- CDTG $29,765,205.00
- TENX N/A
- Revenue This Year
- CDTG N/A
- TENX N/A
- Revenue Next Year
- CDTG N/A
- TENX N/A
- P/E Ratio
- CDTG $5.84
- TENX N/A
- Revenue Growth
- CDTG N/A
- TENX N/A
- 52 Week Low
- CDTG $0.52
- TENX $2.80
- 52 Week High
- CDTG $4.64
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- TENX 57.60
- Support Level
- CDTG N/A
- TENX $5.77
- Resistance Level
- CDTG N/A
- TENX $6.19
- Average True Range (ATR)
- CDTG 0.00
- TENX 0.24
- MACD
- CDTG 0.00
- TENX 0.03
- Stochastic Oscillator
- CDTG 0.00
- TENX 72.33
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.